IN2015DN00688A - - Google Patents
Info
- Publication number
- IN2015DN00688A IN2015DN00688A IN688DEN2015A IN2015DN00688A IN 2015DN00688 A IN2015DN00688 A IN 2015DN00688A IN 688DEN2015 A IN688DEN2015 A IN 688DEN2015A IN 2015DN00688 A IN2015DN00688 A IN 2015DN00688A
- Authority
- IN
- India
- Prior art keywords
- disease
- compound
- alcohol
- disorders
- dyskinesia
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 5
- 201000010099 disease Diseases 0.000 abstract 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 abstract 1
- 208000030090 Acute Disease Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010006895 Cachexia Diseases 0.000 abstract 1
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- 208000012661 Dyskinesia Diseases 0.000 abstract 1
- 208000014094 Dystonic disease Diseases 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 abstract 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 abstract 1
- 208000007201 Myocardial reperfusion injury Diseases 0.000 abstract 1
- 206010028813 Nausea Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010029350 Neurotoxicity Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 208000017442 Retinal disease Diseases 0.000 abstract 1
- 206010038923 Retinopathy Diseases 0.000 abstract 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 abstract 1
- 208000016620 Tourette disease Diseases 0.000 abstract 1
- 206010044221 Toxic encephalopathy Diseases 0.000 abstract 1
- 206010047700 Vomiting Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
- 208000022531 anorexia Diseases 0.000 abstract 1
- 235000021229 appetite regulation Nutrition 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000005796 circulatory shock Effects 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 229960003920 cocaine Drugs 0.000 abstract 1
- 206010061428 decreased appetite Diseases 0.000 abstract 1
- 206010013663 drug dependence Diseases 0.000 abstract 1
- 208000010118 dystonia Diseases 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 208000006454 hepatitis Diseases 0.000 abstract 1
- 231100000283 hepatitis Toxicity 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 206010022437 insomnia Diseases 0.000 abstract 1
- 229960004502 levodopa Drugs 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 230000008693 nausea Effects 0.000 abstract 1
- 230000007135 neurotoxicity Effects 0.000 abstract 1
- 231100000228 neurotoxicity Toxicity 0.000 abstract 1
- 229960002715 nicotine Drugs 0.000 abstract 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 229940127240 opiate Drugs 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000003368 psychostimulant agent Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 208000020431 spinal cord injury Diseases 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/24—Preparation of compounds containing amino groups bound to a carbon skeleton by reductive alkylation of ammonia, amines or compounds having groups reducible to amino groups, with carbonyl compounds
- C07C209/26—Preparation of compounds containing amino groups bound to a carbon skeleton by reductive alkylation of ammonia, amines or compounds having groups reducible to amino groups, with carbonyl compounds by reduction with hydrogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C269/04—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups from amines with formation of carbamate groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
Abstract
A compound having the following structure: or a pharmaceutically acceptable salt or derivative thereof. The compound may be used in the treatment or prevention of a disorder selected from appetite regulation obesity metabolic disorders cachexia anorexia pain inflammation neurotoxicity neurotrauma stroke multiple sclerosis spinal cord injury Parkinson s disease levodopa induced dyskinesia Huntington s disease Gilles de la Tourette s syndrome tardive dyskinesia dystonia amyotrophic lateral sclerosis Alzheimer s disease epilepsy schizophrenia anxiety depression insomnia nausea emesis alcohol disorders drug addictions such as opiates nicotine cocaine alcohol and psychostimulants hypertension circulatory shock myocardial reperfusion injury atherosclerosis asthma glaucoma retinopathy cancer inflammatory bowel disease acute and chronic liver disease such as hepatitis and liver cirrhosis arthritis and osteoporosis.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261674970P | 2012-07-24 | 2012-07-24 | |
PCT/PT2013/000048 WO2014017936A2 (en) | 2012-07-24 | 2013-07-24 | Urea compounds and their use as enzyme inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2015DN00688A true IN2015DN00688A (en) | 2015-06-26 |
Family
ID=48986199
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN688DEN2015 IN2015DN00688A (en) | 2012-07-24 | 2013-07-24 |
Country Status (33)
Country | Link |
---|---|
US (3) | US9549915B2 (en) |
EP (1) | EP2890684B1 (en) |
JP (1) | JP6317345B2 (en) |
KR (1) | KR102137714B1 (en) |
CN (1) | CN104487422B (en) |
AR (1) | AR091888A1 (en) |
AU (1) | AU2013293650B2 (en) |
BR (1) | BR112015001546B1 (en) |
CA (1) | CA2879726A1 (en) |
CL (1) | CL2015000178A1 (en) |
CY (1) | CY1120148T1 (en) |
DK (1) | DK2890684T3 (en) |
ES (1) | ES2667056T3 (en) |
HK (1) | HK1211920A1 (en) |
HR (1) | HRP20180543T1 (en) |
HU (1) | HUE037085T2 (en) |
IL (1) | IL236630B (en) |
IN (1) | IN2015DN00688A (en) |
LT (1) | LT2890684T (en) |
ME (1) | ME03018B (en) |
MX (1) | MX365772B (en) |
NO (1) | NO2923395T3 (en) |
NZ (1) | NZ704651A (en) |
PH (1) | PH12015500156B1 (en) |
PL (1) | PL2890684T3 (en) |
PT (1) | PT2890684T (en) |
RS (1) | RS57146B1 (en) |
RU (1) | RU2685425C2 (en) |
SG (1) | SG11201500498SA (en) |
SI (1) | SI2890684T1 (en) |
TW (1) | TWI624460B (en) |
UA (1) | UA116542C2 (en) |
WO (1) | WO2014017936A2 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR091888A1 (en) | 2012-07-24 | 2015-03-11 | Bial Portela & Ca Sa | UREA COMPOUNDS AND ITS USE AS ENZYMES INHIBITORS |
US9047327B2 (en) | 2012-12-03 | 2015-06-02 | Google Technology Holdings LLC | Method and apparatus for developing a social hierarchy |
ES2640800T3 (en) * | 2013-07-24 | 2017-11-06 | BIAL - PORTELA & Cª, S.A. | Imidazolcarboxamides and their use as FAAH inhibitors |
GB201401198D0 (en) | 2014-01-24 | 2014-03-12 | Bial Portela & Ca Sa | Process for the syntheis of substituted urea compounds |
US10702487B2 (en) | 2017-08-19 | 2020-07-07 | Frimline Private Limited | Pharmaceutical composition for prevention of diet induced obesity |
PH12018000227B1 (en) | 2017-09-05 | 2019-03-11 | Frimline Private Ltd | A pharmaceutical composition for improving or preventing progression of chronic kidney disease |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2458965C3 (en) | 1974-12-13 | 1979-10-11 | Bayer Ag, 5090 Leverkusen | 3-Amino-indazole-N-carboxylic acid derivatives, process for their preparation and pharmaceuticals containing them |
EP0014810A3 (en) | 1979-01-18 | 1980-11-26 | Fbc Limited | Pesticidal pyrazoles, their production, compositions and uses, as well as intermediates and their preparation |
JPH01203366A (en) | 1988-02-10 | 1989-08-16 | Mitsui Petrochem Ind Ltd | N-substituted imidazole derivative |
WO1994010158A1 (en) | 1992-10-28 | 1994-05-11 | Toyama Chemical Co., Ltd. | Novel 1,2-benzisoxazole derivative or salt thereof, and brain protective agent comprising the same |
JP3155009B2 (en) * | 1994-09-26 | 2001-04-09 | 塩野義製薬株式会社 | Imidazole derivatives |
DE102004005172A1 (en) | 2004-02-02 | 2005-08-18 | Aventis Pharma Deutschland Gmbh | Indazole derivatives as inhibitors of the hormone sensitive lipase |
TW200640864A (en) * | 2005-02-17 | 2006-12-01 | Astellas Pharma Inc | Pyridyl non-aromatic nitrogenated heterocyclic-1-carboxylate ester derivative |
FI20075264A0 (en) * | 2007-04-18 | 2007-04-18 | Kuopion Yliopisto | Heterocyclic phenylcarbamates as novel FAAH inhibitors |
WO2009126624A1 (en) * | 2008-04-11 | 2009-10-15 | Bristol-Myers Squibb Company | Triazolo compounds useful as dgat1 inhibitors |
CN102333568B (en) | 2008-12-24 | 2016-01-20 | 比亚尔-珀特拉和Ca股份公司 | Medical compounds |
US9458111B2 (en) * | 2010-07-29 | 2016-10-04 | Bial—Portela & Ca, S.A. | Process for the synthesis of substituted urea compounds |
FR2965262A1 (en) * | 2010-09-24 | 2012-03-30 | Sanofi Aventis | NICOTINAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
AR091888A1 (en) * | 2012-07-24 | 2015-03-11 | Bial Portela & Ca Sa | UREA COMPOUNDS AND ITS USE AS ENZYMES INHIBITORS |
-
2013
- 2013-07-24 AR ARP130102632A patent/AR091888A1/en active IP Right Grant
- 2013-07-24 US US14/416,675 patent/US9549915B2/en active Active
- 2013-07-24 RS RS20180433A patent/RS57146B1/en unknown
- 2013-07-24 SG SG11201500498SA patent/SG11201500498SA/en unknown
- 2013-07-24 NZ NZ704651A patent/NZ704651A/en not_active IP Right Cessation
- 2013-07-24 HU HUE13750166A patent/HUE037085T2/en unknown
- 2013-07-24 CN CN201380038982.7A patent/CN104487422B/en not_active Expired - Fee Related
- 2013-07-24 PL PL13750166T patent/PL2890684T3/en unknown
- 2013-07-24 SI SI201330990T patent/SI2890684T1/en unknown
- 2013-07-24 LT LTEP13750166.4T patent/LT2890684T/en unknown
- 2013-07-24 ES ES13750166.4T patent/ES2667056T3/en active Active
- 2013-07-24 RU RU2015104097A patent/RU2685425C2/en active
- 2013-07-24 PT PT137501664T patent/PT2890684T/en unknown
- 2013-07-24 ME MEP-2018-100A patent/ME03018B/en unknown
- 2013-07-24 MX MX2015000968A patent/MX365772B/en active IP Right Grant
- 2013-07-24 JP JP2015524220A patent/JP6317345B2/en not_active Expired - Fee Related
- 2013-07-24 AU AU2013293650A patent/AU2013293650B2/en not_active Ceased
- 2013-07-24 EP EP13750166.4A patent/EP2890684B1/en active Active
- 2013-07-24 UA UAA201500932A patent/UA116542C2/en unknown
- 2013-07-24 WO PCT/PT2013/000048 patent/WO2014017936A2/en active Application Filing
- 2013-07-24 BR BR112015001546-8A patent/BR112015001546B1/en not_active IP Right Cessation
- 2013-07-24 DK DK13750166.4T patent/DK2890684T3/en active
- 2013-07-24 IN IN688DEN2015 patent/IN2015DN00688A/en unknown
- 2013-07-24 CA CA2879726A patent/CA2879726A1/en not_active Abandoned
- 2013-07-24 KR KR1020157004412A patent/KR102137714B1/en active IP Right Grant
- 2013-07-24 TW TW102126473A patent/TWI624460B/en not_active IP Right Cessation
- 2013-11-20 NO NO13857025A patent/NO2923395T3/no unknown
-
2015
- 2015-01-11 IL IL236630A patent/IL236630B/en active IP Right Grant
- 2015-01-23 CL CL2015000178A patent/CL2015000178A1/en unknown
- 2015-01-23 PH PH12015500156A patent/PH12015500156B1/en unknown
- 2015-12-23 HK HK15112632.2A patent/HK1211920A1/en not_active IP Right Cessation
-
2016
- 2016-12-19 US US15/383,879 patent/US10023541B2/en active Active
-
2018
- 2018-04-04 HR HRP20180543TT patent/HRP20180543T1/en unknown
- 2018-04-23 CY CY20181100426T patent/CY1120148T1/en unknown
- 2018-07-09 US US16/030,384 patent/US11046654B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2015DN00688A (en) | ||
NZ593418A (en) | Imidazole compounds for use as enzyme inhibitors | |
PH12020550768A1 (en) | Compositions and methods of use of phorbol esters | |
IL274648A (en) | New catecholamine prodrugs for use in the treatment of parkinson's disease | |
MX360871B (en) | New compositions for treating neurological disorders. | |
IL237369A0 (en) | Methods of treating alzheimer's disease and pharmaceutical compositions thereof | |
SI2197883T1 (en) | Catecholamine derivative useful for the treatment of parkinson's disease | |
EP2195084A4 (en) | Method of treating parkinson's disease and other movement disorders | |
EP2120580A4 (en) | Compositions and methods for the treatment of metabolic disorders | |
MX2020007318A (en) | Heterocyclic compound. | |
WO2010127143A3 (en) | Neuroprotective ganoderma compositions and methods of use | |
GB201310150D0 (en) | Methods and compositions relating to alzheimer's disease | |
EP2946792A4 (en) | THERAPEUTIC AGENT AND THERAPEUTIC METHOD RELATING TO 1,25D3-MARRS FOR NEUROLOGICAL DISEASE SUCH AS ALZHEIMER'S DISEASE& xA; | |
FR3026042B1 (en) | PROCESS FOR THE PREPARATION OF A MOLTEN-BROWN MACROALGUE POWDER AND PROCESS FOR PRODUCING RIGID OBJECTS THEREFROM | |
WO2010085799A9 (en) | Compositions and method for the treatment of parkinson's disease | |
PL3352742T3 (en) | Compositions comprising triterpenoids for the treatment of alzheimer's disease and parkinson's disease | |
HRP20171378T1 (en) | Imidazolecarboxamides and their use as faah inhibitors | |
WO2013033602A3 (en) | Fatty acid amides, compositions and methods of use | |
JP2016525543A5 (en) | ||
IL265656A (en) | Compositions and methods for treating alzheimer's disease and parkinson's disease | |
SG11201405904XA (en) | Process for producing n-phenyl-n'-phenylsulfonyl piperazine derivative and intermediate thereof | |
GB201015747D0 (en) | Therapeutic target and compound screen for parkinson's disease | |
GB201015771D0 (en) | Therapeutic target and compound screen for parkinson's disease | |
MX2017012239A (en) | Methods and compositions for the intravenous administration of fumarates for the treatment of neurological diseases. | |
GB201417776D0 (en) | The device ive invented is amachine that creates electromagnetic waves that reduces the chances of people getting cancer by up to 85% I have also designed a m |